Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part.

Once the MTD has been defined, the MTD expansion part will be opened for enrollment.
Breast Cancer|Colon Cancer|Ovarian Cancer|Endometrium Cancer
DRUG: BKM120
Maximum Tolerated Dose (MTD) of BKM120, throughout the study
Safety and tolerability of BKM120, throughout the study|Pharmacokinetics of BKM120, throughout the study|Changes in tumor metabolic activity, throughout the study|Pharmacodynamics of BKM120, throughout the study|Clinical tumor response in patients with tumors that show PI3K pathway activation, throughout the study
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part.

Once the MTD has been defined, the MTD expansion part will be opened for enrollment.